CATALYSTReuters • 2h ago
Indian shares rise on Iran war talks, Reliance earnings beat - ReutersIndian shares rise on Iran war talks, Reliance earnings beat Reuters
Why LIMN Stock slipped -0.86% Today — RQD Quant Desk Flash
$2.90 -0.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.89
Liminatus Pharma Inc. (Class A) (LIMN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $3.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LIMN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LIMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Liminatus Pharma Inc. (Class A) (NASDAQ: LIMN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $2.90 (-0.86% 1D, market cap $3.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LIMN ranks #491 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LIMN compare to CRIS and PMCB in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LIMN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRIS (Curis Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and PMCB (PharmaCyte Biotech Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -30.2%, cap $3.6M). Among the 5-stock peer group, LIMN leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LIMN?
▼
Per LIMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971387), Liminatus Pharma Inc. (Class A) generated $0 in revenue, -$10.2M in net income, and -$10.0M in free cash flow against $512.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.89 (-0.34%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-5.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LIMN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY LIMN SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (33% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.4 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$3.76-19.1% Next Q
53
Q2 (-2Q)Grade C-$3.04-3.3% Next Q
50
Q3 (-1Q)Grade D$2.94-1.4% Next Q
48
CurrentGrade D$2.90-6.3% Hist 90D α
45
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LIMN Turnaround Squeeze
While LIMN currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.66) and Max Pain ($3.05) forces dealer call-delta covering toward $148.58.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LIMN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LIMN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LIMN Stock slipped -0.86% Today — RQD Quant Desk Flash
Liminatus Pharma Inc. (Class A) (LIMN) slipped -0.86% to $2.90, trading at 2% of its 52-week range ($2.75 – $141.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($2.75 – $141.5) with RSI-14 at 34.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.90 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live LIMN Headlines & Catalysts
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 5h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 7h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 8h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 10h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 11h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 12h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LIMN)
- ✓Walkthrough of LIMN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LIMN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.57%🛡️ HOLDING TREND SUPPORT
2026-10-30O $2.98H $3.00L $2.75C $2.90VOL 13.0K
RES: $7.02SUP: $2.16SMA50: $3.66SMA200: $11.10
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LIMN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LIMN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LIMN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LIMN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LIMN)
Health Care Rank #491 of 1016
⚔️ CRIS vs LIMN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LIMN vs. CRIS, PMCB, CELZ, BTTC)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Liminatus Pharma Inc. (Class A) (LIMN) ranks #491 by composite RQD confidence (45/100, grade D) and #963 by equity capitalization ($3.9M). Within this direct 5-issuer industry benchmark cohort, LIMN leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with LIMN at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LIMN
ACTIVE
Liminatus Pharma Inc. (Class A) | D | 45/100 | — | — | -35.0% | -0.86% | $3.9M | Benchmark Subject |
| CRIS Curis Inc. | D- | 40/100 | — | — | -35.0% | +20.82% | $3.7M | /cris-vs-limn → |
| PMCB PharmaCyte Biotech Inc. | D- | 40/100 | — | — | -30.2% | -0.78% | $3.6M | /pmcb-vs-limn → |
| CELZ Creative Medical Technology Holdings Inc. | E | 27/100 | — | 63.4% | -35.0% | -5.78% | $5.2M | /celz-vs-limn → |
| BTTC Black Titan Corporation | D | 48/100 | — | — | — | +4.23% | $5.3M | /bttc-vs-limn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001971387In its most recent audited fiscal period (FY2025, filed 2025-12-31), Liminatus Pharma Inc. (Class A) (LIMN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.2M, operating cash flow of -$10.0M, and free cash flow of -$10.0M (-587.5% YoY). On the balance sheet, LIMN closed FY2025 with $512.8K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$10.2M | -$10.0M | -$10.0M | $512.8K | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$3.5M | -$1.5M | -$1.5M | $5.4M | — |
3. LIMN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LIMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Liminatus Pharma Inc. (Class A) (NASDAQ: LIMN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $2.90 (-0.86% 1D, market cap $3.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LIMN ranks #491 in composite RQD confidence.
How does LIMN compare to CRIS and PMCB in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LIMN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRIS (Curis Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and PMCB (PharmaCyte Biotech Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -30.2%, cap $3.6M). Among the 5-stock peer group, LIMN leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LIMN?
Per LIMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971387), Liminatus Pharma Inc. (Class A) generated $0 in revenue, -$10.2M in net income, and -$10.0M in free cash flow against $512.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LIMN trading relative to its 50-day, 200-day, and 52-week technical levels?
LIMN last traded at $2.90 (-0.86% on volume of 28,826 shares), positioning the stock -20.77% below its 50-day simple moving average ($3.66) and -73.87% below its 200-day simple moving average ($11.10). Across its 52-week range of $2.75 to $141.50, LIMN sits at the 0.1% percentile with a 14-day RSI of 34.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.54 to $3.26).
LIMN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LIMN stock moving today?
Why LIMN Stock slipped -0.86% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.